MedTrace Logo

A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy

NCT02839460 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-04-11

No results posted yet for this study

Summary

This is a single center, prospective biomarker study to evaluate serum levels of TWEAK and expression levels of TWEAK and Fn14 in muscle biopsies from patients with sarcopenia as well as healthy, physically active controls.

Conditions

Interventions

PROCEDURE

Outpatient Muscle Biopsy

Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • University of Florida

    lead OTHER

Principal Investigators

  • Stephen D Anton, PhD · University of Florida

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-03-31
Completion
2019-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02839460 on ClinicalTrials.gov